What is Nanalysis?
Nanalysis operates at the intersection of advanced physics and industrial utility, specializing in the development and manufacturing of compact magnetic resonance (MR) spectrometers. By eliminating the need for liquid helium or complex cryogens, the company has effectively democratized access to high-resolution NMR spectroscopy. Their 60 and 100 MHz devices serve as critical infrastructure for professionals in the oil and gas, pharmaceutical, mining, and biotechnology industries. Through its focus on miniaturization and operational efficiency, Nanalysis has established itself as a leader in the transition toward portable, high-throughput analytical instrumentation, moving beyond traditional, bulky laboratory equipment to provide real-time, on-site chemical analysis capabilities.
How much funding has Nanalysis raised?
Nanalysis has raised a total of $5.6M across 2 funding rounds:
Series A
$568K
Grant
$5M
Series A (2015): $568K with participation from Valhalla Private Capital
Grant (2022): $5M led by Prairies Economic Development Canada
Key Investors in Nanalysis
Valhalla Private Capital
Valhalla Private Capital is a full-service corporate finance firm and angel network operator in Western Canada, providing early-stage ventures with essential mentorship, M&A advisory, and investment capital.
Prairies Economic Development Canada
A government agency focused on fostering economic growth and innovation within the Canadian prairie provinces through strategic grants and development initiatives.
What's next for Nanalysis?
With the recent influx of capital, Nanalysis is poised to enter a new phase of enterprise-level growth. The strategic roadmap likely involves expanding its manufacturing capacity to meet the rising demand for cryogen-free MR systems across international markets. Furthermore, the company is expected to invest heavily in R&D to refine its MRI technology, potentially unlocking new applications in point-of-care diagnostics and advanced material science. As the firm matures, the focus will shift toward deepening its footprint in the pharmaceutical and chemical sectors, where the demand for rapid, reliable, and cost-effective analytical data is at an all-time high. This funding round provides the necessary runway to solidify its competitive advantage and drive long-term shareholder value.
See full Nanalysis company page
